Browsing by Author Ribas, Antoni

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 22  next >
Issue DateTitleAuthor(s)Citation
2014Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trialKefford, Richard (Rick); Boasberg, Peter; Chmielowski, Bartosz; Daud, Adil; Dronca, Roxana; Ebbinghaus, Scot; Elassaiss-Schaap, Jeroen; Gangadhar, Tara C.; Gergich, Kevin; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Iannone, Robert; Joseph, Richard W.; Joshua, Anthony M.; Kang, Peter; Li, Xiaoyun; Mateus, Christine; Patnaik, Amita; Postow, Michael; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Western Clinical School: Westmead Millennium InstituteAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial, The Lancet, vol.384, 9948, 2014,pp 1109-1117
2016Association of pembrolizumab with tumor response and survival among patients with advanced melanomaHersey, Peter; Daud, Adil; et al, Various; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joshua, Anthony M.; Kefford, Richard F; Patnaik, Amita; Ribas, Antoni; Wolchok, Jedd D.; Northern Clinical School: SurgeryAssociation of pembrolizumab with tumor response and survival among patients with advanced melanoma, JAMA: The Journal of the American Medical Association, vol.315, 15, 2016,pp 1600-1609
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2018Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanomaHersey, Peter; Anderson, James; Daud, Adil; Diede, Scott J; Dronca, Roxana; Ebbinghaus, Scot; Gangadhar, Tara C.; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Joseph, Richard W.; Joshua, Anthony M.; Kefford, Richard; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Wolchok, Jedd D.; Zarour, Hassane; Zhang, Jin; Northern Clinical School: SurgeryDurable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma, Journal of Clinical Oncology, vol.36, 17, 2018,pp 1668-1674
2016Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with PembrolizumabHersey, Peter; Daud, Adil; et al, Various; Hamid, Omid; Hodi, F. Stephen; Hwu, Wen-Jen; Kefford, Richard F.; Patnaik, Amita; Ribas, Antoni; Robert, Caroline; Weber, Jeffrey; Northern Clinical School: SurgeryEvaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab, Journal of Clinical Oncology, vol.34, 13, 2016,pp 1510-1517
2016Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsLong, Georgina; Davies, Michael; Flaherty, Keith; Grob, Jean-Jacques; Lane, Stephen; Legenne, Philippe; Mak, Carmen; Nathan, Paul; Ribas, Antoni; Robert, Caroline; Schadendorf, D; Northern Clinical School: MedicineFactors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials, The Lancet Oncology, vol.17, 12, 2016,pp 1743-1754
2012Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistanceKefford, Richard (Rick); Long, Georgina; Scolyer, Richard; Chodon, Thinle; Dahlman, Kimberly; Kong, Xiangju; Koya, Richard; Lee, H; Lee, Mi-Kyung; Lo, Roger; Moriceau, Gatien; Nelson, Stanley F.; Ng, Charles; Ribas, Antoni; Shi, Hubing; Sosman, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: PathologyMelanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance, Nature Communications, vol.3, 20122, 2012,pp 1-8
2012New challenges in endpoints for drug development in advanced melanomaHersey, Peter; Flaherty, Keith; Gogas, Helen; Kirkwood, John M; Middleton, Mark; Ribas, Antoni; Sondak, Vernon; Northern Clinical School: SurgeryNew challenges in endpoints for drug development in advanced melanoma, Clinical Cancer Research, vol.18, 2, 2012,pp 336-341
2014A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF InhibitionKefford, Richard (Rick); Long, Georgina; Scolyer, Richard; Chodon, Thinle; Hong, Aayoung; Hugo, Willy; Kong, Xiangju; Koya, Richard; Lo, Roger; Moriceau, Gatien; Ng, Charles; Ribas, Antoni; Shi, Hubing; Song, Chunying; Yu, Clarissa; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: PathologyA Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition, Cancer Discovery, vol.4, 1, 2014,pp 69-79
2017Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyLong, Georgina; Andtbacka, R; Cebon, Jonathan Simon; Dummer, R; et al, Various; Malvehy, Josep; Michielin, Olivier; Olszanski, Anthony; Puzanov, Igor; Ribas, Antoni; VanderWalde, Ari; Northern Clinical School: MedicineOncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy, Cell, vol.170, 6, 2017,pp 1109-1119
2017Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Carlino, Matteo; Long, Georgina; Arance, A; Daud, Adil; et al, Various; Grob, Jean Jacques; Larkin, James; Lotem, Michal; McNeil, Catriona M.; Mortier, Laurent; Ribas, Antoni; Schachter, Jacob; Western Clinical School: Medicine (Westmead); Northern Clinical School: MedicinePembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), The Lancet, vol.390, 10105, 2017,pp 1853-1862
2013Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF InhibitorKefford, Richard (Rick); Long, Georgina; et al, Various; Fecher, Leslie A.; Gonzalez, Rene; Hwu, Patrick; Infante, Jeffrey; Kim, Kevin; McArthur, Grant A.; Millward, Michael; Pavlick, Anna C.; Ribas, Antoni; Sosman, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentrePhase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor, Journal of Clinical Oncology, vol.31, 4, 2013,pp 482-489
2013Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic MelanomaKefford, Richard (Rick); Long, Georgina; Amaravadi, Ravi; Arya, Niki; Ascierto, Paolo; et al, Various; Grob, Jean-Jacques; Guckert, Mary; Hamid, Omid; Kim, Kevin; Lebbe, Celeste; Minor, David; O'Hagan, Anne; Ribas, Antoni; Schadendorf, D; Simeone, Ester; Wilhelm, Tabea; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentrePhase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.31, 26, 2013,pp 3205-3211
2013Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaKefford, Richard (Rick); et al, Various; Garbe, Claus; Gogas, Helen; Haanen, John; Linette, Gerald; Lorigan, Paul; Marmol, Maribel; Marshall, Margaret A.; Punt, Cornelis J.A.; Ribas, Antoni; Schachter, Jacob; Western Clinical School: Westmead Millennium InstitutePhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma, Journal of Clinical Oncology, vol.31, 5, 2013,pp 616-622
2012Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF InhibitorsKefford, Richard (Rick); Long, Georgina; Pupo, Gulietta; Bacchiocchi, Antonella; Chmielowski, Bartosz; Dahlman, Kimberly; Halaban, Ruth; Kong, Xiangju; Koya, Richard; Lo, Roger; Moriceau, Gatien; Nazarian, Ramin; Ribas, Antoni; Shi, Hubing; Sosman, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Western Clinical School: Medicine (Westmead)Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors, Cancer Discovery, vol.2, 5, 2012,pp 414-424